Biomarkers for prenatal diagnosis of congenital cytomegalovirus
The invention provides compositions and methods useful for early detection of congenital CMV infection, predicting the likelihood and severity of congenital CMV disease, and monitoring the efficacy of therapeutic approaches. Compositions of the present invention include biomarkers that are differentially expressed in CMV-infected mothers and fetuses compared to uninfected individuals.
1. A method of diagnosing congenital cytomegalovirus (CMV) infection, the method comprising the steps of:
(a) obtaining amniotic fluid from a subject;
(b) contacting the amniotic fluid with monoclonal antibodies that specifically bind a panel of selected markers that comprise the group sFlt-1 and cmvIL-10; and;
(c) determining whether the markers are differentially expressed in the amniotic fluid compared to amniotic fluid from a non-infected subject; thereby providing a diagnosis for congenital CMV infection.
2. The method of claim 1 , wherein the determining step comprises an enzyme-linked immunosorbant assay (ELISA) or a mass spectroscopy.
3. The method of claim 1 , wherein the monoclonal antibodies are detectably labeled.
4. The method of claim 1 , further comprising adjusting a therapy based on a determination of efficacy.
5. A method of predicting congenital cytomegalovirus (CMV) disease, the method comprising the steps of:
(a) obtaining amniotic fluid from a subject;
(b) contacting the amniotic fluid with monoclonal antibodies that specifically bind to a panel of selected markers that comprise the group sFlt-1 and cmvIL-10; and;
(c) determining whether the markers are differentially expressed in the amniotic fluid compared to amniotic fluid from a non-infected subject; thereby predicting congenital CMV disease.
6. A method of determining the efficacy of therapy for congenital cytomegalovirus (CMV) infection, the method comprising the steps of:
(a) obtaining amniotic fluid from a subject;
(b) contacting the amniotic fluid with antibodies that specifically bind a panel of selected markers that comprise the group sFlt-1 and cmvIL-10; and;
(c) determining whether the markers are differentially expressed in the ample amniotic fluid compared to amniotic fluid obtained from the subject at an earlier time; thereby determining the efficacy of therapy.
7. A kit comprising reagents that specifically bind to a panel of CMV-associated markers, wherein the kit comprises reagents that bind the group comprising sFlt-1 and cmvIL-10.
8. The kit of claim 7 wherein the reagents are monoclonal antibodies.